Wolfe Research Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its target price increased by Wolfe Research from $350.00 to $375.00 in a report issued on Friday morning,MarketScreener reports. They currently have an outperform rating on the medical instruments supplier’s stock.

Several other analysts also recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. Piper Sandler increased their price target on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Canaccord Genuity Group boosted their price objective on Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a report on Monday, September 29th. Royal Bank Of Canada upped their target price on Insulet from $350.00 to $365.00 and gave the stock an “outperform” rating in a research report on Friday, October 10th. Finally, Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $370.76.

Insulet Trading Down 1.1%

Shares of NASDAQ:PODD traded down $3.58 during mid-day trading on Friday, hitting $319.82. The company had a trading volume of 677,166 shares, compared to its average volume of 721,278. The firm has a fifty day moving average price of $325.06 and a 200 day moving average price of $309.40. The company has a market capitalization of $22.51 billion, a PE ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet has a one year low of $230.05 and a one year high of $353.50.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same period in the prior year, the firm earned $1.08 earnings per share. Insulet’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts forecast that Insulet will post 3.92 EPS for the current year.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The SEC filing for this sale provides additional information. 0.39% of the stock is owned by company insiders.

Institutional Trading of Insulet

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Insulet by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after purchasing an additional 87,845 shares in the last quarter. Geode Capital Management LLC increased its stake in Insulet by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock valued at $603,211,000 after buying an additional 58,309 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after buying an additional 297,734 shares in the last quarter. Groupama Asset Managment boosted its stake in shares of Insulet by 0.4% in the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after buying an additional 3,759 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Insulet in the second quarter valued at approximately $324,689,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.